2. PROTAC PI3K/Akt/mTOR Apoptosis
  3. PROTACs mTOR PI3K Apoptosis
  4. GP262

GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3Kα and mTOR with DC50 values of 42.23 nM, 227.4 nM and 45.4 nM, respectively in MDA-MB-231 cells. GP262 induces degradation of p110α and p110γ with a DC50 of 227.4 and 42.23 nM. GP262 efficient modulates the PI3K/AKT/mTOR pathway, achieving degradation through the ubiquitin-proteasome system (UPS). GP262 also exhibits robust antiproliferative activity and induces apoptosis in vitro. GP262 exhibits tumor growth suppression capability and biosafety profile. GP262 can be used for leukemia and triple-negative breast cancer (TNBC) .

(Pink: mTOR and PI3K ligand (HY-203618); Blue: VHL ligand (HY-125845); Black: linker).

For research use only. We do not sell to patients.

GP262

GP262 Chemical Structure

Size Price Stock Quantity
5 mg Get quote 4 - 5 Weeks 3 - 4 Weeks 5 - 6 Weeks 4 - 5 weeks
10 mg Get quote 4 - 5 Weeks 3 - 4 Weeks 5 - 6 Weeks 4 - 5 weeks
25 mg Get quote 4 - 5 Weeks 3 - 4 Weeks 5 - 6 Weeks 4 - 5 weeks
50 mg Get quote 4 - 5 Weeks 3 - 4 Weeks 5 - 6 Weeks 4 - 5 weeks
100 mg Get quote 4 - 5 Weeks 3 - 4 Weeks 5 - 6 Weeks 4 - 5 weeks
200 mg   Get quote  
500 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

GP262 Related Antibodies

Top Publications Citing Use of Products

View All PROTACs Isoform Specific Products:

View All Isoforms
von Hippel-Lindau (VHL) Cereblon MDM2 cIAP1

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3Kα and mTOR with DC50 values of 42.23 nM, 227.4 nM and 45.4 nM, respectively in MDA-MB-231 cells. GP262 induces degradation of p110α and p110γ with a DC50 of 227.4 and 42.23 nM. GP262 efficient modulates the PI3K/AKT/mTOR pathway, achieving degradation through the ubiquitin-proteasome system (UPS). GP262 also exhibits robust antiproliferative activity and induces apoptosis in vitro. GP262 exhibits tumor growth suppression capability and biosafety profile. GP262 can be used for leukemia and triple-negative breast cancer (TNBC) [1].
(Pink: mTOR and PI3K ligand (HY-203618); Blue: VHL ligand (HY-125845); Black: linker).

IC50 & Target[1]

p110α

227.4 nM (DC50)

p110γ

42.23 nM (ED50)

mTOR

45.4 nM (Kd)

In Vitro

GP262 (0-5 μM, 0-24 h) efficiently reduces PI3K and mTOR Levels and this degradation is attenuated upon 26S proteasome inhibition, can be blocked under high concentration competition (MG132 (HY-13259) and VH032 (HY-120217)) and depends on VHL recruitment in MDA-MB-231 cells[1].
GP262 (8-1000 nM) significantly inhibits proliferation and induces programmed cell death (apoptosis), reveals dose-dependent growth inhibition with IC50 values of 68.0 nM (in MDA-MB-231), 161.6 nM (in MCF-7), and 124.2 nM (in MDA-MB-361), achieving maximum inhibition (Imax) of 65.4, 83.4, and 97.7% respectively, impairs colony formation in MDA-MB-231 cells at 200 nM, and has a degradation efficacy against mTOR and PI3Kα with IC50 values of 167.6 and 40 nM in MCF-7 cells[1].
GP262 (8-5000 nM, 24 h) demonstrates concentration-dependent reduction of PI3Kγ protein levels in THP-1 cells and antiproliferative effects in OCI-AML3 (IC50 = 44.3 nM) and THP-1 cells (IC50 = 48.3 nM)[1].
GP262 (1000 nM, 12 h) increases apoptosis to 32.1% in MDA-MB-231 cells[1].
GP262 (0.03125-2 μM) reveals dissociation constants with Kd of 0.867 μM for PI3Kα and 0.479 μM for mTOR[1].
GP262 induces polyubiquitination-dependent proteasomal degradation[1].
GP262 exhibits excellent kinase selectivity for the PI3K family and mTOR, thereby inducing widespread transcriptomic alterations including multiple differentially expressed genes (DEGs) associated with cell cycle regulation, cancer-related processes, and apoptosis, which collectively demonstrate significant enrichment and profound impact on cell cycle-related pathways in MDA-MB-231 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GP262 Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 8, 40, 200, 1000 and 5000 nM
Incubation Time: 0, 3, 6, 9, 12 and 24 h
Result: Induced degradation of p110α with a DC50 of 227.4 nM and a Dmax of 71.3%.
Induced degradation of p110γ with a DC50 of 42.23 nM and a Dmax of 88.6%.
Induced degradation of mTOR with a DC50 of 45.4 nM and a Dmax of 74.9%.
Significantly inhibited AKT activation (p-AKT) without affecting the total AKT protein levels.
Reduced p85, p-GSK and p-4EBP1 protein level.
Induced time-dependent proteolysis of mTOR and p110α at 1 μM, exhibiting significant degradation within 12 h and maximal efficiency by 24 h, and this effect was markedly attenuated upon 26S proteasome inhibition and was also inhibited by siRNA-mediated VHL knockdown (500 nM, 24 h).

Western Blot Analysis[1]

Cell Line: THP-1 cells
Concentration: 8, 40, 200, 1000 and 5000 nM
Incubation Time: 24 h
Result: Demonstrated concentration-dependent reduction of PI3Kγ protein levels (DC50 = 88.4 nM) with >70% maximal degradation efficiency achieved after 24-h treatment.
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUClast AUCinf MRTINF_obs F ClF_obs C0 AUC0-inf Vd
Rat[1] 15 mg/mL i.p. 8.25 h 7.00 h 816 ng/mL 11068 ng·h/mL 12469 ng·h/mL 11.1 h 51.5 % / / / /
Rat[1] 5 mg/mL i.v. 7.6 h / / 7848 ng·h/mL / 2.68 h / 10.5 mL/min/kg 50993 ng/mL 8073 ng·h/mL 6.96 L/kg
In Vivo

GP262 (15 or 25 mg/kg, i.p., daily for 20 consecutive days) effective reduces target protein levels (PI3K and mTOR) in tumor tissues and significant tumor growth inhibition and exhibits excellent safety and tolerability without causing significant systemic toxicity or organ damage in MDA MB-231 triple-negative breast cancer xenograft NOD-SCID mice model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MDA MB-231 cells induced-female NOD-SCID mice (60-70 days old, 22-24 g)[1]
Dosage: 15 or 25 mg/kg
Administration: i.p., daily for 20 consecutive days
Result: Showed 57.8% tumor growth inhibition at 15 mg/kg and 79.2% tumor growth inhibition at 25 mg/kg.
Maintained body weight fluctuations within 10%.
Reduced PI3K and mTOR protein expression.
Decreased expression of the proliferation marker KI67.
Showed no significantly inflammatory infiltration, necrosis, or structural abnormalities in major organs (heart, liver, and kidney).
Molecular Weight

1073.31

Formula

C56H72N12O8S
SMILES

O=C(NC1=CC=C(C=C1)C(NCCCCCCCCC(N[C@H](C(N2C[C@@H](C[C@H]2C(NCC3=CC=C(C=C3)C4=C(N=CS4)C)=O)O)=O)C(C)(C)C)=O)=O)NC5=CC=C(C=C5)C6=NC(N7CCOCC7)=NC(N8CCOCC8)=N6
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GP262 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GP262GP 262GP-262PROTACsmTORPI3KApoptosisMammalian target of RapamycinPhosphoinositide 3-kinasePROTACapoptosisLeukemiatriple-negative breast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GP262
Cat. No.:
HY-180261
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.